5 Expert Tips to Avoid FDA Form 483s in Your Analytical Laboratory

FDA Form 483s, more commonly referred to as 483s in the pharmaceutical industry, is a nonconformance issued by the Food and Drug Administration at the close of an inspection. Feared by everyone in the industry, this type of observation can elicit panic in the recipient, extra work for the recipient’s employees, and raise questions for those working with the recipient.

How to Avoid a Form 483s in your Analytical Laboratory

Depending on the circumstances and the items reviewed, you may be unable to avoid receiving a Form 483 at the close of your inspection. However, you can implement five simple processes from our experts in your laboratory to help reduce your chances of getting one of those feared and dreaded Form 483s at the close of your next FDA inspection.

(1) A Daily Laboratory Monitoring Program

You have probably heard the saying, “you don’t get a second chance to make a first impression.” This is even true when the FDA pays your laboratory a visit. Walking into a neat and orderly space gives the inspectors the impression that you must have good procedures and care about your work.

Since the audit tour is typically very early in the inspection, if an audit tour goes badly, it can set the inspectors up to expect a less-than-favorable visit.

Implementing a daily laboratory monitoring program can ensure that the laboratory space is neat and orderly for an unexpected visit by the FDA. Performing a daily inspection of the laboratory space, typically by a quality assurance employee, can allow time to correct items found in the laboratory that may trigger an inspector to issue an observation.

Reducing clutter, ensuring expired materials have been removed from the working space, and checking for proper and consistent labeling practices are among a few items that can be reviewed during daily QA inspections.

Daily inspections also set the expectation for all employees that order, cleanliness, and company procedures should always be followed and not only during times of inspection.

(2) Data Review Process

When reviewing data, ensure it follows the ALCOA + principles:

  • (A)ttributable: identifiable to the person or system that generated the data
  • (L)egible: data can be read and understood
  • (C)ontemporaneous: recording data when it occurs
  • (O)riginal: original recording of data should be the main record; not copies or transcriptions
  • (A)ccurate: a reflection of what happened; error-free

+

  • Available: accessible
  • Enduring: ensuring data is available long-term
  • Consistent: chronological and in an expected sequence
  • Complete: nothing has been deleted or lost
Data Review Process

(3) Internal Audit Program

Internal audits are performed to assure compliance to all applicable requirements and to discover areas that may need improvement. The audits should be performed by a qualified auditor that is unrelated to the activity being audited. Some areas that should be considered for internal auditing are:

  • Data Records
  • Equipment Records
  • Electronic Systems
  • Investigations/Deviations
  • Quality Department

(4) Continuous Improvement Plan

Areas of improvement may be discovered during daily laboratory monitoring or internal audits. Often, reducing the frequency of issues can be achieved through SOP revisions, implementation of new processes or forms, or additional training provided to employees.

(5) Effectiveness Checks

Once improvement initiatives have been completed, there must be a process for determining if the actions actually resolved the recurring issue. If not, a new improvement plan may be needed. Effectiveness check processes should include a defined timeline for checking the effectiveness, parameters to evaluate the success, and a plan for those identified as not successful.

Considerations for Implementation of New Processes

It’s not always easy to implement new processes in organizations; there are things to consider. The resources, time, and cost of a new process must be evaluated prior to creating and launching them. Also, changes may not come easy for some employees, and you may be met with resistance. Getting buy-in from upper management and those affected by the new processes is important.

If any of these processes are missing from your laboratory, reaching out to the MMS Quality & Compliance Team is a great first step! Our experienced and knowledgeable team can help you implement these processes. Showing continual improvement of processes may help you avoid one of those ever so unpopular and dreaded 483s. Reach out to our team at info@mmsholdings.com.

Suggested For You

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

June 14th, 2024

A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives

June 6th, 2024

Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling

perspectives

May 10th, 2024

Psychedelics in Drug Development and Regulatory Considerations Part I: Benefit-Risk

perspectives

April 29th, 2024

Validation of Clinical Dashboards for Decision Making